Ascendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga reports. They currently have a $170.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s price target points to a potential upside of 15.97% from the stock’s previous close.

Several other analysts have also weighed in on ASND. Evercore ISI upgraded shares of Ascendis Pharma A/S to a “strong-buy” rating in a research report on Monday, August 26th. Stifel Nicolaus initiated coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 target price on the stock. TD Cowen decreased their target price on shares of Ascendis Pharma A/S from $175.00 to $157.00 and set a “buy” rating on the stock in a research report on Wednesday, September 4th. The Goldman Sachs Group lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $195.00 and gave the company a “buy” rating in a research report on Tuesday, August 13th. Finally, Bank of America boosted their price target on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and a consensus price target of $193.77.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $146.59 on Monday. The company’s fifty day moving average is $132.51 and its two-hundred day moving average is $136.47. Ascendis Pharma A/S has a 52-week low of $85.29 and a 52-week high of $161.00. The firm has a market capitalization of $8.54 billion, a price-to-earnings ratio of -14.97 and a beta of 0.63.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vestal Point Capital LP bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $78,719,000. GSA Capital Partners LLP bought a new stake in Ascendis Pharma A/S in the first quarter valued at approximately $992,000. Price T Rowe Associates Inc. MD increased its stake in Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock valued at $269,374,000 after purchasing an additional 336,976 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $5,779,000. Finally, Perceptive Advisors LLC bought a new stake in Ascendis Pharma A/S in the fourth quarter valued at approximately $16,648,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.